Skip to main content
Premium Trial:

Request an Annual Quote

Kerala, India Biotech Park Moves Forward: Four Acres Earmarked for Incubator

NEW YORK, March 25 - The Indian state of Kerala has moved forward with plans to develop a biotech park in its capital, a regional website reported today.

 

The biotech park will occupy 25 acres in the state's capital of Thiruvananthapuram, (also known as Trivandrum), with a technology incubation center on four acres, and the remaning 21 acres as a business improvement zone with developed plots, the government-owned Kerala Industrial Infrastructure Development Corporation (KINFRA) states on its website. Pharmaceutical companies will be invited to locate facilities in the park.

 

The state government has allocated Rs. 300 million ($6.3 million) for the park, and the Indian government is likely to match these funds equally, according to the regional website, keralanext.com.

 

The "thrust areas" in which the park's developers would like its industrial denizens to focus include immunodiagnostics and vaccines, industrial enzymes, plant tissue culture, biopesticides, and biofertilizers, KINFRA said.

 

Additionally, the RajivGandhiCenterfor Biotechnology, which is located in Thiruvananthapuram, will be a node of this park, director R. V. Thampan told keralanext.com. The Rajiv Gandhi Center researchers study everything from bioactive peptides involved in controlling the fungal pathogen responsible for black pepper quick wilt disease, to the expression of biodegrading genes.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.